Who are FOLFOX/ FOLFIRI with bevacizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab, FOLFOXIRI with bevacizumab, carboplatin paclitaxel bevacizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfox-folfiri-with-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

FOLFOX/ FOLFIRI with bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FOLFOX/ FOLFIRI with bevacizumab (FOLFOX/ FOLFIRI with bevacizumab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with anti-angiogenic monoclonal antibody. Area: Oncology.

phase 3 Chemotherapy combination with anti-angiogenic monoclonal antibody DNA (chemotherapy); VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FOLFOX/ FOLFIRI with bevacizumab (FOLFOX/ FOLFIRI with bevacizumab) — Dutch Colorectal Cancer Group. FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FOLFOX/ FOLFIRI with bevacizumab TARGET	FOLFOX/ FOLFIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (chemotherapy); VEGF (bevacizumab)
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab)
FOLFOXIRI with bevacizumab	FOLFOXIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)
carboplatin paclitaxel bevacizumab	carboplatin paclitaxel bevacizumab	Gruppo Oncologico Italia Meridionale	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with anti-angiogenic monoclonal antibody class)

Dutch Colorectal Cancer Group · 2 drugs in this class
Gruppo Oncologico Italia Meridionale · 1 drug in this class
Lee's Pharmaceutical Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOLFOX/ FOLFIRI with bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/folfox-folfiri-with-bevacizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab